Mysterious Oropouche virus is spreading: what you should know

Update: The US Centers for Disease Control and Prevention said 27 August that more than 20 US travelers returning from Cuba have been identified as having Oropouche virus.
Once confined to the Amazon region, the mysterious insect-borne virus that causes Oropouche fever has been expanding its range since late 2023, raising international concern. There have been more than 8,000 confirmed human infections in the Americas so far this year, most of them in Brazil, but Peru, Bolivia, Colombia and Cuba have also been affected.
In July, authorities in Brazil reported the deaths of two adults from the disease — the first fatalities recorded since the virus was identified almost 70 years ago. Brazilian officials are also investigating cases of fetal deaths and malformations that might have been caused by the virus, which investigations have shown can spread from a pregnant person to the fetus1. There are no vaccines or treatments for the disease.
Earlier this month, the Pan American Health Organization upgraded its risk level for Oropouche from moderate to high, citing the virus’s geographical spread and the occurrence of fatal cases, which are notable for a disease that has historically been known to cause mild to moderate symptoms. On 23 August, the World Health Organization published a note stating that the public-health risk posed by the virus is high at the regional level and low at the global level. The US Centers for Disease Control and Prevention has advised close surveillance of people returning from affected areas. Cases of Oropouche infection have been identified in people who have travelled to the United States, Spain, Italy and Germany from Brazil and Cuba.
Nature spoke to Gonzalo Bello, a public-health specialist at the Oswaldo Cruz Institute in Rio de Janeiro, Brazil, who has studied the lineage of the Oropouche virus currently spreading in the Americas.
Oropouche is a virus of the genus Orthobunyavirus. It differs from other better-known vector-borne viruses like dengue, Zika, yellow fever or Chikungunya because it is typically transmitted to humans by a midge, Culicoides paraensis, rather than by mosquitoes. But we cannot rule out the possibility that other vectors might be involved. [The virus has been found in other insects, including the mosquito Culex quinquefasciatus.]
It was discovered in 1955 in Trinidad and Tobago, in the Caribbean. In 1960, it was first detected in Brazil from a blood sample taken from a sloth. Since the 1960s, it has been identified in outbreaks in humans more or less intermittently in the Amazon region [a vast area that spans nine countries in South America]. That’s why we say it’s a re-emerging virus, because it has been circulating for many decades at least in the Amazon, which is considered an endemic region.
When it comes to the Amazon region, it is difficult to say whether the current outbreak is larger than in previous decades. For the first time, a molecular surveillance diagnostic system is being implemented, something that didn’t exist in past epidemics.

Climate change will force new animal encounters — and boost viral outbreaks

The geographic extension of the outbreak does represent a change. The number of municipalities and states affected is much higher. Additionally, the virus has spread outside the Amazon region. Again, we don’t know whether this is the first time because there was no surveillance of Oropouche outside the Amazon before.
What also raises concern is the finding of local transmission in Cuba for the first time. and imported cases in Europe and in the United States. As the Culicoides paraensis midge is found throughout the Americas, from the United States to Argentina, whenever there are infected people and there are vectors, there may be local transmission events. So, any infected individual can generate a local epidemic, that’s the main concern.
The symptoms are similar to those of other arboviruses such as dengue: fever, headache, muscle or joint pain, pain behind the eyes, vomiting and nausea. So it’s very difficult to diagnose an Oropouche infection only from symptoms, you really need to have a molecular laboratory diagnosis. A few cases may evolve into more severe forms, with neurological or hemorrhagic manifestations, but most cases are mild and resolve after seven or eight days.
For the first time, the presence of antibodies against Oropouche, indicative of a recent infection, was found in newborns with microcephaly. This suggests an association, but because of the study’s limitations, it wasn’t possible to establish a causal relationship between infection during intrauterine life and the neurological malformations.

Massive mosquito factory in Brazil aims to halt dengue

But it was possible to establish proof of mother-to-child transmission in cases of fetal and newborn death. In one case, a pregnant woman had symptoms of Oropouche and, weeks later, fetal death was confirmed. The Oropouche genome was detected in several organs of the fetus. In another recent case, a pregnant woman tested positive for Oropouche. The baby was born but died [weeks] later. Post-mortem examination identified the virus genome in various tissues, including the brain.
There were also two deaths of previously healthy young women who had symptoms similar to severe dengue. They were not pregnant. These were the first cases in the literature classified as deaths associated with Oropouche infection.
It is not yet possible to establish how frequently these fatal cases would be happening, either in adults or fetuses. So far, there is no evidence that the symptoms have changed compared with previous outbreaks.